1. Naming prescription drugs in promotional copy
Botulinum toxin (Botox, Dysport, Xeomin, Nuceiva), hyaluronic-acid dermal fillers (Juvederm, Restylane, RHA), and bimatoprost (Latisse) are prescription drugs in Canada. Section 3 of the Food and Drugs Act read with Schedule A restricts how prescription products can be advertised to the general public. Health Canada's guidance on the distinction between advertising and other activities sets out when a website crosses from information into advertising. The Vancouver audit found this is the most universally broken rule: every audited page named a prescription drug brand in promotional context.
